Q2 EPS Estimates for Nuvation Bio Lowered by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Stock analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for Nuvation Bio in a research report issued on Tuesday, May 5th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.14) for the quarter, down from their previous estimate of ($0.12). HC Wainwright has a "Buy" rating and a $17.00 price target on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Nuvation Bio's Q3 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.33) EPS.

Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.04. The company had revenue of $83.23 million for the quarter, compared to the consensus estimate of $66.22 million. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%.

Several other equities analysts also recently commented on NUVB. Wedbush reiterated an "outperform" rating and set a $11.00 price target on shares of Nuvation Bio in a report on Tuesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nuvation Bio in a report on Tuesday, April 21st. UBS Group cut their price target on shares of Nuvation Bio from $10.00 to $7.00 and set a "neutral" rating on the stock in a report on Tuesday, March 3rd. Truist Financial set a $13.00 price target on shares of Nuvation Bio in a report on Tuesday, January 27th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $20.00 price target on shares of Nuvation Bio in a report on Tuesday. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Nuvation Bio presently has an average rating of "Moderate Buy" and an average target price of $12.50.

Nuvation Bio Stock Performance

Shares of NYSE:NUVB opened at $5.04 on Thursday. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -11.73 and a beta of 1.51. Nuvation Bio has a 12 month low of $1.57 and a 12 month high of $9.75. The firm's 50-day moving average is $4.70 and its 200 day moving average is $5.94. The company has a current ratio of 7.44, a quick ratio of 6.81 and a debt-to-equity ratio of 0.15.

Hedge Funds Weigh In On Nuvation Bio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its stake in shares of Nuvation Bio by 852.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company's stock valued at $24,270,000 after purchasing an additional 2,424,109 shares in the last quarter. Armistice Capital LLC boosted its stake in shares of Nuvation Bio by 359.2% during the third quarter. Armistice Capital LLC now owns 2,296,000 shares of the company's stock valued at $8,495,000 after purchasing an additional 1,796,000 shares in the last quarter. Capricorn Fund Managers Ltd bought a new position in shares of Nuvation Bio during the fourth quarter valued at approximately $14,236,000. Millennium Management LLC boosted its stake in shares of Nuvation Bio by 52.4% during the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company's stock valued at $6,642,000 after purchasing an additional 1,298,131 shares in the last quarter. Finally, SymBiosis Capital Partners LLC bought a new position in shares of Nuvation Bio during the fourth quarter valued at approximately $11,200,000. Institutional investors own 61.67% of the company's stock.

Insider Buying and Selling

In other news, insider Kerry Wentworth sold 200,000 shares of the firm's stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $4.52, for a total transaction of $904,000.00. Following the transaction, the insider directly owned 53,000 shares of the company's stock, valued at approximately $239,560. This trade represents a 79.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dongfang Liu sold 50,000 shares of the stock in a transaction on Friday, April 17th. The stock was sold at an average price of $5.02, for a total value of $251,000.00. Following the transaction, the insider directly owned 18,000 shares in the company, valued at $90,360. The trade was a 73.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 286,750 shares of company stock worth $1,339,118. Corporate insiders own 30.11% of the company's stock.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company's pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.